A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy

This study is a prospective single arm multicenter intervention study aimed at evaluating the feasibility of using organoid drug sensitivity results to guide first-line treatment of advanced leiomyosarcoma. The primary endpoint of the study is objective response rate (ORR). The secondary endpoint are Progression Free Survival (PFS) and 6-month PFS rate.

NCT Number	NCT07405346
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Collaborators: Fudan University, Zhejiang Cancer Hospital, West China Hospital, Xiangya Hospital of Central South University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital of Guangxi Medical University, Hubei Cancer Hospital, Henan Cancer Hospital, Second Xiangya Hospital of Central South University, Tianjin Hospital, First Affiliated Hospital of Fujian Medical University
Conditions	Advanced Leiomyosarcoma
Enrollment	50 participants
Start Date	2026-03-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-12